Stockreport

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

SeaStar Medical Holding Corporation  (ICU) 
PDF Data illustrate the potential of QUELIMMUNE™? with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children w [Read more]